Home Technical Performance and Diagnostic Utility of the New Elecsys® Neuron-Specific Enolase Enzyme Immunoassay
Article
Licensed
Unlicensed Requires Authentication

Technical Performance and Diagnostic Utility of the New Elecsys® Neuron-Specific Enolase Enzyme Immunoassay

  • Thomas Muley , Werner Ebert , Petra Stieber , Hannelore Raith , Stefan Holdenrieder , Dorothea Nagel , Heinrich Fürst , Hans-Jürgen Roth , Hilmar Luthe , Bert G. Blijenberg , Eberhard Gurr , Wolfgang Uhl , Joachim von Pawel and Peter Drings
Published/Copyright: June 1, 2005
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 41 Issue 1

Abstract

This international multicenter study was designed to evaluate the technical performance of the new double-monoclonal, single-step Elecsys neuron-specific enolase (NSE) enzyme immunoassay (EIA) and to assess its utility as a sensitive and specific test for the diagnosis of small-cell lung cancer (SCLC). Intra- and inter-assay coefficients of variation, determined in five control or serum specimens in six laboratories, ranged from 0.7 to 5.3 (inter-laboratory median: 1.3%) and from 1.3 to 8.5 (inter-laboratory median: 3.4%), respectively. Laboratory-to-laboratory comparability was excellent with respect to recovery and inter-assay coefficients of variation. The test was linear between 0.0 and 320 ng/ml (highest measured concentration). There was a significant correlation between NSE concentrations measured using the Elecsys NSE and the established Cobas Core NSE EIA II in all subjects (n = 723) and in patients with lung cancer (n = 333). However, NSE concentrations were systematically lower (approximately 9%) with the Elecsys NSE than with the comparison test. Based on a specificity of 95% in comparison with the group suffering from benign lung diseases (n = 183), the cut-off value for the discrimination between malignant and benign conditions was set at 21.6 ng/ml. NSE was raised in 73.4% of SCLC patients (n = 188) and was significantly higher (p < 0.01) in extensive (87.8%) as opposed to limited disease (56.7%). NSE was also elevated in 16.0% of the cases with nonsmall cell lung cancer (NSCLC, n = 374). It is concluded that the Elecsys NSE EIA is a reliable and accurate diagnostic procedure for the measurement of NSE in serum samples. The special merits of this new assay are the wide measuring range (according to manufacturer's declaration up to 370 ng/ml) and a short incubation time of 18 min.

:
Published Online: 2005-06-01
Published in Print: 2003-01-27

Copyright © 2003 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. Evidence-Based Laboratory Medicine: Addressing Bias, Generalisability and Applicability in Studies on Diagnostic Accuracy. The STARD Initiative
  2. Semen Polymorphonuclear Neutrophil Leukocyte Elastase as a Diagnostic and Prognostic Marker of Genital Tract Inflammation – A Review
  3. Total Oxyradical Scavenging Capacity toward Different Reactive Oxygen Species in Seminal Plasma and Sperm Cells
  4. Identification of New Polymorphisms in the CACNA1S Gene
  5. 3-Nitrotyrosine in Atherosclerotic Blood Vessels
  6. Molecular Diagnosis of Cystic Fibrosis: Comparison of Four Analytical Procedures
  7. Assessment of Intestinal Permeability: Enzymatic Determination of Urinary Mannitol, Raffinose, Sucrose and Lactose on Hitachi Analyzer
  8. Effects of Calcium Carbonate, Magnesium Oxide and Sodium Citrate Bicarbonate Health Supplements on the Urinary Risk Factors for Kidney Stone Formation
  9. Glycerol Metabolism and the Determination of Triglycerides –Clinical, Biochemical and Molecular Findings in Six Subjects
  10. Plasma Lipid Composition and LDL Oxidation
  11. Modified Method to Measure Nasal Potential Difference
  12. Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD Initiative
  13. Novel and Traditional Biomarkers of Bone Turnover in Postmenopausal Women
  14. Urinary Plasma Protein Patterns in Acute Prostatitis
  15. Adequate Sampling in Cryoglobulinaemia: Recommended Warmly
  16. A New Modification of the Chiron ACS Assay for Total Prostate-Specific Antigen Achieves Equimolar Response Characteristics and Improves the Detection of Prostate Cancer
  17. Technical Performance and Diagnostic Utility of the New Elecsys® Neuron-Specific Enolase Enzyme Immunoassay
  18. Measurements of Complement Factor H-Related Protein (BTA-TRAK™ Assay) and Nuclear Matrix Protein (NMP22 Assay) – Useful Diagnostic Tools in the Diagnosis of Urinary Bladder Cancer?
  19. Erratum: The 18th International Congress of Clinical Chemistry and Laboratory Medicine. Special Supplement Abstracts Issue 2002
  20. Meetings and Awards
Downloaded on 13.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2003.017/html
Scroll to top button